Our latest research is published in ๐๐ฐ๐ญ๐ฆ๐ค๐ถ๐ญ๐ข๐ณ ๐๐ฉ๐ฆ๐ณ๐ข๐ฑ๐บ ๐๐ฏ๐ค๐ฐ๐ญ๐ฐ๐จ๐บ:
“๐๐จ๐ฆ๐ฉ๐๐ซ๐๐ญ๐ข๐ฏ๐ ๐๐ฏ๐๐ฅ๐ฎ๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐จ๐ง๐๐จ๐ฅ๐ฒ๐ญ๐ข๐ ๐ฏ๐ข๐ซ๐ฎ๐ฌ๐๐ฌ ๐ซ๐๐ฏ๐๐๐ฅ๐ฌ ๐จ๐ฉ๐ฉ๐จ๐ฌ๐ข๐ง๐ ๐ฉ๐ซ๐๐๐๐ซ๐๐ง๐๐๐ฌ ๐๐จ๐ซ ๐ ๐ฅ๐ข๐จ๐๐ฅ๐๐ฌ๐ญ๐จ๐ฆ๐ ๐ฌ๐ฎ๐๐ญ๐ฒ๐ฉ๐๐ฌ”
Glioblastoma is the most aggressive primary brain tumor in adults and remains extremely difficult to treat. Oncolytic viruses, viruses that selectively infect and kill cancer cells while stimulating an anti-tumor immune response, are a promising therapeutic strategy, but patient responses are highly variable.
In this study, we identified two main groups of oncolytic viruses based on their activity profiles, each showing distinct preferences for glioblastoma subtypes and opposite associations with tumor-associated biological processes.
These findings highlight the importance of matching the right virus to the right tumor and support the development of personalized and combinatorial oncolytic virotherapy approaches for glioblastoma patients.
Congratulations to Tine Deconinck and all co-authors who contributed to this work!
